Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05604222
Other study ID # STUDY22050099
Secondary ID 1R01AG076575-01
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 5, 2023
Est. completion date March 31, 2027

Study information

Verified date June 2024
Source University of Pittsburgh
Contact Shachi Tyagi, MD
Phone 412-647-1274
Email tyagis@upmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Urgency urinary incontinence (UUI) is common in older people and vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will investigate the role of adding behavioral sleep intervention to the standard pharmacotherapy in treatment of UUI among older adults, and the brain mechanisms involved in continence by evaluating brain changes. This will expand the current knowledge of how the sleep affects bladder control, and better characterize the brain mechanisms in maintaining continence.


Description:

Urgency urinary incontinence (UUI), a form of overactive bladder (OAB), is prevalent (36% of women over age 65), morbid and costly ($83 billion/year), and treatment is problematic. Current treatment is largely bladder centric has limited efficacy,and adherence rates fade to 21% at 12 months. The researchers believe that a complimentary approach, one that also addresses etiology beyond the bladder may enhance treatment success. Up to 50% of older adults complain of poor sleep and nighttime bladder symptoms (nocturia) are considered the major cause. However, the relationship between sleep and the bladder is complex and bidirectional. Poor sleep not only exacerbates daytime lower urinary tract symptoms (LUTS), but can also cause these, increasing the risk of LUTS by up to 55% over 5 years. Sleep disruption increases anxiety and impairs daytime attention, both of which affect bladder control. Consistent with findings in anxiety disorders and attention control, poor sleep is linked to media prefrontal cortex (mPFC) hypoactivity, a region the investigators have identified as key to executive control of voiding and to therapeutic response to biofeedback-assisted pelvic floor muscle therapy. Hence, the investigators posit that enhanced mPFC function through improved sleep might ameliorate bladder control. Despite evidence of a bidirectional relationship, the impact of sleep treatment on UUI has never been assessed. The researchers prior study demonstrated that improving sleep using Brief Behavioral Treatment of Insomnia (BBTI), a simple intervention for insomnia, improved both sleep and nocturia in older adults, yet its impact on UUI and mechanism of action is not known. Our exploratory analysis of sleep and voiding data from 20 older adults with UUI and nocturia showed that with behavioral sleep intervention alone, 24-hour UUI episodes decreased with prolongation of uninterrupted sleep before the first awakening to void (r=-0.50, p=0.02), and increased proportion of deep sleep (r=-0.56, p=0.01). Hence, the researchers postulate that addressing sleep in patients with UUI and nocturia may further potentiate bladder-focused UUI treatment. The efficacy of mirabegron, a β3- adrenoceptor agonist is comparable to first-line antimuscarinic pharmacotherapy for UUI, with fewer side effects, but it has only a modest effect on nocturia. Although these drugs show statistically significant improvement in LUTS, drug compliance remains poor secondary to modest perceived clinical benefit. The researchers central hypothesis is that comorbid insomnia contributes to poor therapeutic response for UUI and concurrent insomnia treatment will improve outcomes. Specifically, addition of BBTI to drug therapy will improve sleep, nocturia, and daytime LUTS, likely mediated by improvement of mPFC function. The researchers propose an 8-week randomized controlled trial of mirabegron+BBTI vs. mirabegron alone for UUI in 100 women (aged ≥60), assessing both clinical and neural effects of treatment. The researchers will also assess durability of the combination therapy at 6 months. This design encompasses the role of sleep in OAB treatment, insight into the central and peripheral effects of mirabegron and BBTI, and response durability.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 31, 2027
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender Female
Age group 60 Years and older
Eligibility Inclusion Criteria: - ambulatory women aged 60+ years - urgency incontinence or urge-predominant mixed incontinence (able to differentiate between stress symptoms-cough, laugh, exercise-and leakage following the sudden onset of a strong urge to void that is difficult to defer during questioning on telephone screening) occurring at least five times weekly for = 3 months despite treatment for reversible causes - nocturia =2 each night - subjects with current or previous use of anticholinergic medications will be considered for the study if willing to go through a washout period of at least 4 weeks of duration Exclusion Criteria: - contraindication to any of the drugs used (e.g., mirabegron, prophylactic antibiotics) - cognitive impairment (MOCA score <24 or inability to accurately complete a voiding diary, perform a 24-hour pad test, reliably take daily medication, or comply with fMRI testing) - prior treatment with intradetrusor onabotulinum toxin or sacral neuromodulation. - spinal cord injury; history of pelvic irradiation, advanced uterine or bladder cancer; multiple sclerosis - urethral obstruction; urinary retention [PVR >200 ml] - interstitial cystitis; artificial sphincter implant - medical instability or expected change in medication during the study - conditions that preclude fMRI testing, such as history of claustrophobia, history or suspicion of implanted metal or electronic object - requirement for intravenous antibiotics for bacterial endocarditis prophylaxis or presence of multiple allergies to the antibiotics available in our protocol - chronic or recurrent bowel issues, e.g. IBS, colitis, fecal incontinence - known allergy to study medication or interaction with current medications - severe uncontrolled hypertension >180 mmHg systolic or >100 mmHg diastolic

Study Design


Intervention

Drug:
Mirabegron 50 MG
Medication to treat overactive bladder
Behavioral:
Brief Behavioral Treatment for Insomnia
A behavioral intervention for insomnia

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Shachi Tyagi National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incontinence episodes The number of incontinence episodes Baseline to 8 weeks
Secondary Structural brain changes Change in grey and white matter volume on MRI compared between the two arms. Grey matter and white matter volume of important brain structures will be compared via tractography. Baseline to 8 weeks
Secondary Functional brain changes Change in brain functional response to an infusion/withdrawal protocol compared between the two arms. Changes are displayed as a map of t-values for each voxel of the brain, showing likelihood of statistical significance of changes. Baseline to 8 weeks
Secondary Nocturia episodes The number of nocturia episodes Baseline to 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Completed NCT02904759 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects Phase 3
Completed NCT02905682 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects Phase 3
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT01694498 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3
Completed NCT01684800 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women Phase 2
Completed NCT01222598 - A Study of Minirin Melt in Patients With Nocturia N/A
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Completed NCT01486706 - Efficacy and Safety of Gabapentin in Treating Overactive Bladder Phase 2/Phase 3
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Recruiting NCT05874375 - UCon Treatment of Overactive Bladder (OAB) in Males N/A
Completed NCT01223937 - Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients Phase 3
Withdrawn NCT01018225 - Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness Phase 4
Completed NCT05222477 - Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes N/A
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Completed NCT02440841 - Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon Phase 1
Completed NCT02068560 - The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion N/A
Completed NCT01357356 - Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia Phase 2/Phase 3
Completed NCT02151253 - Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Phase 2/Phase 3